-
Incannex Healthcare (IXHL) Appoints Douglas B. Kirsch to its Board
-
Incannex Healthcare (IXHL) achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
-
Incannex Healthcare (IXHL) Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
-
Incannex Healthcare (IXHL) Advances IHL-42X RePOSA Trial to Phase 3
-
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025
-
Incannex Healthcare (IXHL) Enters Agreement to Cancel Remaining Series A Warrants
-
Incannex Healthcare (IXHL) Files for 65.97M Share Offering by Selling Stockjolders
-
Incannex Healthcare (IXHL) Prices 11.57M Share Offering $1.08/sh
-
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
-
Incannex Healthcare (IXHL) Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X
-
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
-
Incannex Healthcare (IXHL) Files for 61.39M Share Offering by Selling Stockholders
-
Incannex Healthcare (IXHL) Appoints Lou Barbato as Chief Medical Officer
-
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
-
Incannex Healthcare (IXHL) Announces Strategic Financing for up to $60 Million with Arena Investors
-
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

